Can Intismeran Autogene Plus Pembrolizumab Improve Melanoma Outcomes?By Karam Khaddour, MD, MSNovember 20th 2026ESMO data show the phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab improved recurrence-free survival in resected stage IIB to IV melanoma.